Semaglutide & Liraglutide are GLP drugs that now form the first line of treatment for diabetes and weight loss. Semaglutide alone did sales in excess of $14B, and thanks to its meteoric rise, Novo Nordisk’s market cap crossed Denmark’s GDP (not comparable, I know, but you get the point). If you happen to know a diabetologist or an endocrinologist, talk to them; they’ll tell you about the revolution. Once they hit the generics market (semaglutide will be out of patent in 2026), manufacturers and branded comps will have a feast. Neuland is one of the initial manufacturers making progress in this space. So yes, Neuland is more special than people realise.
| Subscribe To Our Free Newsletter |
